Poster SESSIONS
50
Poster, 23 June 2014
P-04-022
The efficacy of vilazodone in achieving re-
mission in patients with major depressive
disorder: Post hoc analyses of a phase iv trial
Leslie Citrome, Suffern, USA
C. Gommoll, X. Tang, R. Nunez, G. Forero,
M. Mathews
P-04-023
Clinical relevance of levomilnacipran er
treatment in patients with major depres-
sive disorder: Improvements in functional
impairment categories
Andrew Cutler, Maitland, USA
C. Gommoll, C. Chen, W. M. Greenberg, A. Ruth,
A. Ho Reese
P-04-024
Cellular adhesion molecules and cognitive
functions in depression
Dunja Degmecic, Osijek, Croatia
T. Bacun, L. Glavaš-Obrovac, V. Šeric, S. Topic,
A. Vcev
P-04-025
Potential antidepressant-like effect of the
brain penetrant neuropeptide Y Y2 receptor
antagonist SF-11 in the rat model of depres-
sion induced by astrocyte ablation
Helena Domin, Krakow, Poland
B. Szewczyk, M. Wozniak, M. Smialowska
P-04-026
Effects of vortioxetine on cognitive symp-
toms of major depressive disorder (MDD)
Maurizio Fava, Boston, USA
S. Lophaven, C. Olsen
P-04-027
The efficacy of levomilnacipran er in the
treatment of patients with depression-as-
sociated fatigue symptoms
Marlene Freeman, Boston, USA
M. Fava, C. Gommoll, C. Chen, W. M. Green-
berg, A. Ruth, J. Terner-Rosenthal
P-05
POSTER SESSION
17:15–18:45
Hall B
Schizophrenia A
P-05-001
Switching to antipsychotic monotherapy
can improve attention and social activity in
chronic schizophrenia patients
Hikaru Hori, Kitakyushu, Japan
R. Yoshimura, A. Katsuki, A. Sugita, K. Atake,
J. Nakamura
P-05-002
Efficacy of aripirpazole once-monthly in
Asian patients with schizophrenia: Second-
ary efficacy outcomes in a multicenter, ran-
domized, double-blind, non-inferiority study
versus oral aripiprazole
Jun Ishigooka, Tokyo, Japan
J. Nakamura, N. Shimizu, A. Study group
P-05-003
Hyperprolactinemia during antipsychotics
treatment has a risk of venous thromboem-
bolism
Masamichi Ishioka, Hirosaki, Japan
N. Yasui-Furukori, N. Sugawara, H. Furukori,
S. Kudo, K. Nakamura
P-05-004
Microglial activation in first-episode and
drug-naïve schizophrenia
Yasuhide Iwata, Hamamatsu, Japan
K. Suzuki, N. Mori
P-05-005
Association study of H2AFZ with schizo-
phrenia in a Japanese case-control sample
Daisuke Jitoku, Tokyo, Japan
N. Yamamoto, Y. Iwayama, M. Umino, A. Um-
ino, A. Uezato, A. Kurumaji, T. Yoshikawa,
T. Nishikawa
P-05-006
Functional role of serotonin 5-HT5A recep-
tors in cognition: Mechanism of action study
with a selective antagonist ASP5736
Noriyuki Yamamoto, Tsukuba, Japan
J. Yarimizu, M. Yamazaki, K. Harada, M. Oka-
be, K. Ni
P-05-007
ASP5736, a novel serotonin 5-HT5A receptor
antagonist, ameliorates positive symptom,
cognitive impairments and mood dysfunction
in animal models of schizophrenia
Mayako Yamazaki, Tsukuba, Ibaraki, Japan
J. Yarimizu, K. Harada, N. Yamamoto, M. Oka-
be, T. Shimada, K. Ni
P-05-008
ASP5736, a novel serotonin 5-HT5A receptor
antagonist, ameliorates positive symptom
and cognitive impairments in animal mod-
els of schizophrenia: Combination studies
with olanzapine
Junko Yarimizu, Tsukuba-Shi, Japan
M. Yamazaki, K. Harada, N. Yamamoto, M. Oka-
be, K. Ni
